Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2,648

Samumed in $438 Million Deal to Develop Anti-agingTherapies

Today, we were pleased to hear that Samumed, a San Diego-based biotech company working on regenerative medicine, has just raised $438 million towards developing anti-aging therapies.

SAN DIEGO – August 6, 2018 – Samumed, LLC, announced today that it has closed its A-6 Round of equity issuance with $438 million, bringing its total equity raised to date to more than $650 million. The pre-money valuation for the round was $12 billion.

“We appreciate the strong support from our investors,” said Osman Kibar, Ph.D., Chief Executive Officer of Samumed, “and we are now in a fortunate position to both move our later stage programs to commercialization, as well as expand on our earlier stage science and clinical portfolio.”

Ichor Therapeutics Announces The Formation of Grapeseed.bio

Ichor Therapeutics, a life science company in Lafayette, New York, is one of the big players in the world of rejuvenation biotechnologies. Since its founding in 2013, it has been growing and expanding its portfolio of companies working on therapies against the diseases of aging; on August 1, 2018, Ichor announced the formation of its strategic fund, Grapeseed.bio.

What is Grapeseed.bio

This new fund and accelerator program is meant to provide young life science startups with seed funding up to $100,000, technical training, mentorship, and full access to Ichor’s large research laboratory.

Can the US stop the scientific brain drain to China?

The United States is still the preeminent location for scientific research, but this is not a given, and we should not take it for granted. The new policies being implemented by China, and especially their ambition to attract outside talent, could quickly drain the lifeblood of our scientific institutions. Without a determined effort to attract, support, and retain leading researchers, we cannot expect to drive the breakthroughs, technologies, and medicines of the future. Massachusetts has admirably made a strong commitment to biotechnology through the Life Sciences Initiative. But will this be enough to sustain the scientific ecosystem of the entire country?

The United States is in danger of losing its primacy in scientific research.

Journal Club July 2018 — CRISPR may cause unwanted mutations

The July edition of the Journal Club has us taking a look at a recent paper that casts doubt and concern over the use of CRISPR Cas9 for gene editing.

If you like watching these streams and/or would like to participate in future streams, please consider supporting us by becoming a Lifespan Hero: https://www.lifespan.io/hero

The paper we are discussing can be found here: https://www.nature.com/articles/nbt.

Exeter University boffins have discovered ‘elixir of life’

For centuries humans have sought the ‘elixir of life’ – a mythical potion that supposedly would grant the drinker eternal life.

Now Exeter scientists believe they may have found the secret to a longer, healthier life.

New compounds developed and tested at the University of Exeter have brought the dream a step closer and paved the way for “anti-degeneration” drugs that could not only extend life, but also extend health and may help treat age-related diseases like cancer, dementia and diabetes.

Compounds AP39, AP123, RT01 may reverse ageing in human cell: Study

The compounds — AP39, AP123 and RT01 — have been designed to selectively deliver minute quantities of the gas hydrogen sulphide to the mitochondria in cells and help the old or damaged cells to generate the ‘energy’ needed for survival and to reduce senescence.

In the samples used, the number of senescent cells — older cells that have deteriorated and stopped dividing — was reduced by up to 50 per cent.

The team also identified two splicing factors — a component of cells — that play a key role in when and how endothelial cells become senescent.